Janus Henderson Group PLC Clovis Oncology, Inc. Transaction History

Janus Henderson Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.96 $12,818 - $60,227	-20,347 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.43 - $3.14 $110 - $241	77 Added 0.38%	20,347 $42,000
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.76 $27,645 - $48,737	10,239 Added 102.07%	20,270 $55,000
Q3 2021 Nov 16, 2021	BUY	$4.06 - $5.8 $10,742 - $15,346	2,646 Added 35.83%	10,031 $45,000
Q4 2017 Feb 09, 2018	SELL	$57.69 - $84.58 $10.3 Million - $15 Million	-177,826 Reduced 96.01%	7,385 $502,000
Q3 2017 Nov 14, 2017	SELL	$67.17 - $84.81 $2.15 Million - $2.71 Million	-31,994 Reduced 14.73%	185,211 $0
Q2 2017 Aug 17, 2017	BUY	N/A	217,205	217,205 $20.3 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.